Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine against Invasive Pneumococcal Disease in Adults, Japan, 2013-2017

被引：14

作者：

Shimbashi, Reiko ^{[1
,2
]}

Suzuki, Motoi ^{[1
,2
]}

Chang, Bin ^{[1
]}

Watanabe, Hiroshi ^{[3
]}

Tanabe, Yoshinari ^{[4
]}

Kuronuma, Koji ^{[5
]}

Oshima, Kengo ^{[2
]}

Maruyama, Takaya ^{[6
]}

Takeda, Hiroaki ^{[7
]}

Kasahara, Kei ^{[8
]}

Fujita, Jiro ^{[9
]}

Nishi, Junichiro ^{[10
]}

Kubota, Tetsuya ^{[11
]}

Tanaka-Taya, Keiko ^{[1
]}

Matsui, Tamano ^{[1
]}

Sunagawa, Tomimasa ^{[1
]}

Oishi, Kazunori ^{[1
,12
]}

机构：

[1] Natl Inst Infect Dis, Tokyo, Japan

[2] Tohoku Univ, Grad Sch Med, Sendai, Miyagi, Japan

[3] Kurume Univ, Sch Med, Fukuoka, Japan

[4] Niigata Prefectural Shibata Hosp, Niigata, Japan

[5] Sapporo Med Univ, Sch Med, Sapporo, Hokkaido, Japan

[6] Natl Hosp Org Mie Natl Hosp, Tsu, Mie, Japan

[7] Yamagata Saisei Hosp, Yamagata, Japan

[8] Nara Med Univ, Nara, Japan

[9] Univ Ryukyus, Grad Sch Med, Nishihara, Okinawa, Japan

[10] Kagoshima Univ, Grad Sch Med & Dent Sci, Kagoshima, Japan

[11] Kochi Univ, Kochi Med Sch, Kochi, Japan

[12] Toyama Inst Hlth, Toyama, Japan

来源：

EMERGING INFECTIOUS DISEASES | 2020年 / 26卷 / 10期

关键词：

PNEUMONIAE SEROTYPE 12F; CONJUGATE VACCINE; POPULATION; IMPACT; OLDER; SPAIN;

D O I：

10.3201/eid2610.191531

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The decline in the proportion of pneumococcal conjugate vaccine (PCV)-covered serotypes among adult invasive pneumococcal disease (IPD) patients might change the overall effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPSV23) because its effectiveness differs according to serotype. Using the indirect cohort method, we calculated the effectiveness of PPSV23 against IPD among adults in Japan to assess the impact of the national pediatric PCV program. Clinical and epidemiologic information and pneumococcal isolates were collected from IPD patients >= 20 years of age through enhanced IPD surveillance during April 2013-December 2017. Adjusted effectiveness against PPSV23-serotype IPD was 42.2%. Despite a substantial decline in the proportion of 13-valent PCV serotypes during the study period (45% to 31%), the change in effectiveness for PPSV23-serotype IPD was limited (47.1% to 39.3%) and only marginal in the elderly population (39.9% to 39.4%). The pediatric PCV program had limited impact on PPSV23 effectiveness against IPD in adults.

引用

页码：2378 / 2386

页数：9

共 50 条

[31] Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease in Greenland
Nikolova, Kristiana Alexandrova
Andersson, Mikael
Slotved, Hans-Christian
Koch, Anders
VACCINES, 2021, 9 (10)
[32] Safety of varying dosages of 7-valent pneumococcal protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine
Jackson, LA
Neuzil, KM
Whitney, CG
Starkovich, P
Dunstan, M
Yu, OC
Nelson, JC
Feikin, DR
Shay, DK
Baggs, J
Carste, B
Nahm, MH
Carlone, G
VACCINE, 2005, 23 (28) : 3697 - 3703
[33] Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in 23-valent pneumococcal polysaccharide vaccine-naive and previously immunized adult patients with severe chronic kidney disease
Ulanova, Marina
Huska, Brenda
Desbiens, Angele
Gaultier, Gabrielle N.
Domonkos, Victoria
McCready, William G.
VACCINE, 2021, 39 (04) : 699 - 710
[34] Immunogenicity following revaccination or sequential vaccination with 23-valent pneumococcal polysaccharide vaccine (PPSV23) in older adults and those at increased risk of pneumococcal disease: a review of the literature
Cripps, Allan W.
Folaranmi, Temitope
Johnson, Kelly D.
Musey, Luwy
Niederman, Michael S.
Buchwald, Ulrike K.
EXPERT REVIEW OF VACCINES, 2021, 20 (03) : 257 - 267
[35] Serotype-specific effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumococcal pneumonia in adults aged 65 years or older: a multicentre, prospective, test-negative design study
Suzuki, Motoi
Dhoubhadel, Bhim Gopal
Ishifuji, Tomoko
Yasunami, Michio
Yaegashi, Makito
Asoh, Norichika
Ishida, Masayuki
Hamaguchi, Sugihiro
Aoshima, Masahiro
Ariyoshi, Koya
Morimoto, Konosuke
LANCET INFECTIOUS DISEASES, 2017, 17 (03) : 313 - 321
[36] Immunogenicity of the 13-valent pneumococcal conjugate vaccine followed by the 23-valent pneumococcal polysaccharide vaccine in people living with HIV on combination antiretroviral therapy
Garrido, Hannah M. Garcia
Schnyder, Jenny L.
Haydari, Beheshta
Vollaard, Albert M.
Tanck, Michael W. T.
de Bree, Godelieve J.
Meek, Bob
Grobusch, Martin P.
Goorhuis, Abraham
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2022, 60 (02)
[37] Immunogenicity and safety after the third vaccination with the 23-valent pneumococcal polysaccharide vaccine in elderly patients with chronic lung disease
Ohshima, Nobuharu
Akeda, Yukihiro
Nagai, Hideaki
Oishi, Kazunori
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2020, 16 (09) : 2285 - 2291
[38] Revaccination with 23-valent pneumococcal polysaccharide vaccine in the Japanese elderly is well tolerated and elicits immune responses
Kawakami, Kenji
Kishino, Hiroyuki
Kanazu, Shinichi
Toshimizu, Nobuhito
Takahashi, Kenichi
Sterling, Tina
Wang, Meihua
Musey, Luwy
VACCINE, 2016, 34 (33) : 3875 - 3881
[39] Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
Tomczyk, Sara
Bennett, Nancy M.
Stoecker, Charles
Gierke, Ryan
Moore, Matthew R.
Whitney, Cynthia G.
Hadler, Stephen
Pilishvili, Tamara
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT, 2014, 63 (37): : 822 - 825
[40] Cost-Effectiveness Analysis of 23-Valent Pneumococcal Polysaccharide Vaccine Program for the Elderly Aged 60 Years or Older in Shanghai, China
Sun, Xiaodong
Tang, Yuekun
Ma, Xiaoying
Guo, Xiang
Huang, Zhuoying
Ren, Jia
Qiu, Jing
Jiang, Hongli
Lu, Yihan
FRONTIERS IN PUBLIC HEALTH, 2021, 9

← 1 2 3 4 5 →